← Leaderboards
Steven Dubois
Dana-Farber Cancer Inst
$3,581,513
Attributed
$4,828,341
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $629.9K · FY2011–23$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,578,341 · 3
FDA$250,000 · 1
By mechanism
R01$4,336,413 · 3
K23$491,928 · 1
Top collaborators
- Rochelle Bagatell5 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Tracy T Batchelor$27,819,477
- Daphne A. Haas-Kogan$5,585,485
- Franziska Michor$16,040,992
- Rochelle Bagatell$1,843,838
- Cameron Brennan$883,235
Others in their field
Top investigators on “Newly Diagnosed”
- Jeffrey P Krischer · University Of South Florida$201,270,568
- Michael W Weiner · Northern California Institute Res &Educ$79,877,492
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$64,693,871
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$58,285,642
- Diane V Havlir · University Of California, San Francisco$39,712,443
- Olaf Schneewind · University Of California Los Angeles$36,322,144
Research focus
Newly DiagnosedMalignant NeoplasmsDesignTranscriptRelapseChildResponseTumorHigh RiskFutureRadiationMessenger RnaModalityCombined Modality TherapyNeuroblastomaRadiation EffectGenesCancer TherapyNormal Tissue MorphologyPeripheral BloodBlood SpecimenGene ExpressionExposure ToAdult
Grant awards (15)
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma$347,922
R01 · FY2023 · CA · contact PI
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma$594,506
R01 · FY2021 · CA · contact PI
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma$310,299
R01 · FY2020 · CA · contact PI
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma$611,015
R01 · FY2019 · CA · contact PI
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma$629,914
R01 · FY2018 · CA · contact PI
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma$363,425
R01 · FY2017 · CA · contact PI
PhI trial of dual PI3K/BRD4 inhibitor SF1126 in neuroblastoma IND124993 (12/2/14)$250,000
R01 · FY2017 · FD · contact PI
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma$363,426
R01 · FY2016 · CA · contact PI
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma$200,788
R01 · FY2015 · CA · contact PI
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma$144,124
R01 · FY2015 · CA · contact PI
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma$323,237
R01 · FY2014 · CA · contact PI
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma$197,757
R01 · FY2013 · CA · contact PI
Bone Marrow Micrometastatic Disease in Ewing Sarcoma$163,976
K23 · FY2013 · CA · contact PI
Bone Marrow Micrometastatic Disease in Ewing Sarcoma$163,976
K23 · FY2012 · CA · contact PI
Bone Marrow Micrometastatic Disease in Ewing Sarcoma$163,976
K23 · FY2011 · CA · contact PI